PTC-JPM-20240108.pdf

1、PTC Therapeutics JP Morgan 2024Matthew B.Klein,MDCEOPTC Therapeutics 2024Patient Living with PKUPTC Therapeutics JP Morgan 2024This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.All statements contained in this presentatio

2、n,other than statements of historic fact,are forward-looking statements,including statements with respect to 2024 total revenue guidance,2024 operating expenditure guidance and 2024 acquisition related milestone payment guidance,and statements regarding:the future expectations,plans and prospects fo

3、r PTC,including with respect to the expected timing of clinical trials and studies,availability of data,regulatory submissions and responses,commercialization and other matters with respect to its products and product candidates;PTCs strategy,future operations,future financial position,future revenu

4、es,projected costs;the extent,timing and financial aspects of our strategic pipeline prioritization and reductions in workforce;and the objectives of management.Other forward-looking statements may be identified by the words,guidance,plan,anticipate,believe,estimate,expect,intend,may,target,potentia

5、l,will,would,could,should,continue,and similar expressions.PTCs actual results,performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties,including those related to:the outcome of pric

6、ing,coverage and reimbursement negotiations with third party payors for PTCs products or product candidates that PTC commercializes or may commercialize in the future;PTCs ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil,Russia,the European Economic